A Q&A On The Superior Solution for Harvesting Bone Marrow

 

On this episode of the MarketScale Healthcare podcast, Dr. Jeff Chabot, co-founder, director and inventor at Endocellutions, offered some knowledge on regenerative medicine using bone marrow therapies and reveals why the Marrow Cellution aspiration device is superior to traditional harvesting systems.

According to Dr. Chabot, when it comes to harvesting bone marrow, having more of the healing cells in the product is better. In fact, every study that has looked at the long term effects of procedures reveals that more colony forming units (CFU) per ml is associated with better outcomes.

“CFUs are derived uniquely from the bone marrow,” he informed, and went on to say that a higher count generates a richer product of the real architects of repair,” he said.

Traditionally, the way bone marrow is collected often yields contamination with peripheral blood. In fact, the bone marrow aspirates collected using common needles and a centrifuge system isn’t really rich enough to achieve a therapeutic benefit. Enter the Marrow Cellulation device.

“The Marrow Cellution system represents a superior solution to the centrifuge for four reasons,” Dr. Chabot said.

Less volume is required to be drawn from the patient and the volume that is drawn is of higher quality marrow with little contamination of peripheral blood. Eliminating the necessity of a centrifuge results in a fuller complement of cells since most would be thrown away with the plasma layer using the centrifuge system.

“You get more cells per unit volume from the Marrow Cellution system,” Dr. Chabot said.

And finally, Dr. Chabot is of the opinion that the way marrow is collected using the Marrow Cellution system is more reflective of the way the body naturally arranges healing. He went on to express his enthusiasm for groundbreaking medical technologies, saying, “We’re very excited to see such new devices coming along that are really going to advance the potential and opportunities in regenerative medicine.”

References

Single whole blood injections in canine knee are not associated with damage, but repeated injections are: https://www.ncbi.nlm.nih.gov/pubmed/24286243

Use of marrow concentrates with microfracture in equine knee: https://www.ncbi.nlm.nih.gov/pubmed/20720135

Hernigou– greater CFU-f counts associated with better outcomes https://www.ncbi.nlm.nih.gov/pubmed/9587614

Megakaryocyte-bone marrow stromal cell aggregates retain higher potential: https://www.ncbi.nlm.nih.gov/pubmed/15265298

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More